525 reports of this reaction
2.8% of all AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE reports
#3 most reported adverse reaction
DRUG INEFFECTIVE is the #3 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 525 FDA adverse event reports linking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE to DRUG INEFFECTIVE. This represents approximately 2.8% of all 18,930 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a less commonly reported adverse event for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to drug ineffective, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 525 FDA reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 2.8% of all adverse event reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.